Advancing Vaccine Sovereignty in Africa’s Health Systems

In the last five years, Africa's interaction with global vaccine supplies has shown that access to vaccines and biologics is influenced more by established systems than by goodwill or monetary support alone. As international demand for vaccines surged during the COVID-19 pandemic, many African nations found themselves at a disadvantage, reliant on foreign suppliers that delayed access to crucial medical supplies.

A pivotal moment came during the 38th African Union Summit in February 2025, where African leaders resolved that health security, local manufacturing, and system resilience must no longer be seen as external responsibilities but as internal commitments. This shift is essential, given that the continent grapples with frequent disease outbreaks and supply chain disruptions that significantly impact development, political stability, and economic strength.

As of now, the rationale for this commitment remains compelling. Surveillance from the Africa Centres for Disease Control and Prevention revealed a severe cholera outbreak across the continent, prompting concerns over the vulnerability of health systems. The recent spikes in diseases such as cholera and mpox underscore an urgent need for Africa to build internal capacity and reduce its reliance on external resources.

In recent times, strategic initiatives have been launched to revamp vaccine manufacturing in Africa. The African Union has set an ambitious target for the continent to produce 60% of its vaccine needs by 2040 through the Partnerships for African Vaccine Manufacturing (PAVM). This initiative aligns with broader continental frameworks aimed at fostering local production and enhancing health security.

Nonetheless, mere manufacturing capacity will not suffice without bolstering upstream research, regulatory processes, and skilled labor. The current scenario requires investments not only in facilities but also in human capital capable of sustaining manufacturing operations and ensuring effective responses to health emergencies.

Various new financing mechanisms, such as the African Vaccine Manufacturing Accelerator and the Regionalised Vaccine Manufacturing Collaborative, have been established to support this endeavor. These initiatives aim to strengthen the manufacturing landscape while promoting equitable access to vaccines.

Additionally, the framework known as ACHIEVE 2.0 Africa seeks to accommodate these needs by enhancing the underlying systems of vaccine supply. It combines various functions related to drug manufacturing and regulatory processes, ensuring a smooth workflow from research to market delivery.

As these frameworks gain traction, they highlight the necessity for ongoing commitments from African states to align with continental goals. Countries have begun reallocating funds towards local vaccine production, indicated by Nigeria's proposal to train thousands of health professionals to bolster the sector.

Ultimately, Africa's pursuit of vaccine sovereignty reflects broader aspirations for public health independence. The continent's recent resolutions and action plans represent a paradigm shift, recognizing that sustainable health security is vital to economic resilience and collective action amid global crises. The successful realization of these frameworks will determine Africa’s ability to respond to future health challenges effectively.